Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Eledon Pharmaceuticals (ELDN) Shares Issued (2017 - 2025)

Eledon Pharmaceuticals filings provide 4 years of Shares Issued readings, the most recent being $1.6 million for Q4 2017.

  • On a quarterly basis, Shares Issued changed N/A to $1.6 million in Q4 2017 year-over-year; TTM through Dec 2017 was $4.8 million, a 12737.84% increase, with the full-year FY2025 number at $230000.0, up 6.98% from a year prior.
  • Shares Issued hit $1.6 million in Q4 2017 for Eledon Pharmaceuticals, up from -$881000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $97.9 million in Q4 2014 to a low of -$881000.0 in Q3 2017.
  • Median Shares Issued over the past 4 years was $118000.0 (2015), compared with a mean of $8.6 million.
  • The widest YoY moves for Shares Issued: up 2487.5% in 2015, down 99.95% in 2015.
  • Eledon Pharmaceuticals' Shares Issued stood at $97.9 million in 2014, then tumbled by 99.95% to $48000.0 in 2015, then dropped by 22.92% to $37000.0 in 2016, then skyrocketed by 4308.11% to $1.6 million in 2017.
  • The last three reported values for Shares Issued were $1.6 million (Q4 2017), -$881000.0 (Q3 2017), and $3.6 million (Q2 2017) per Business Quant data.